Oncotarget

Research Papers:

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

Yannick Willemen _, Johan M.J. Van den Bergh, Sarah M. Bonte, Sébastien Anguille, Carlo Heirman, Barbara M.H. Stein, Herman Goossens, Tessa Kerre, Kris Thielemans, Marc Peeters, Viggo F.I. Van Tendeloo, Evelien L.J. Smits, Zwi N. Berneman

PDF |  HTML  |  Author Information  |  Order a Reprint

Oncotarget. 2016; 7:73960-73970. https://doi.org/10.18632/oncotarget.12170

Metrics: PDF 331 views  |   HTML 207 views  |   ?  


Abstract

Yannick Willemen1, Johan M.J. Van den Bergh1, Sarah M. Bonte2, Sébastien Anguille1, Carlo Heirman3, Barbara M.H. Stein1, Herman Goossens4, Tessa Kerre2, Kris Thielemans3, Marc Peeters5, Viggo F.I. Van Tendeloo1, Evelien L.J. Smits1,5,*, Zwi N. Berneman1,*

1Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

2Department of Hematology and Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium

3Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium

4Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

5Center for Oncological Research, University of Antwerp, Antwerp, Belgium

*Shared senior authors

Correspondence to:

Yannick Willemen, email: yannick.willemen@uantwerp.be

Keywords: electroporation, hyaluronan-mediated motility receptor, immunotherapy, messenger RNA, vaccination

Received: January 26, 2016     Accepted: September 12, 2016     Published: September 21, 2016

ABSTRACT

We formerly demonstrated that vaccination with Wilms’ tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.

Author Information

Yannick Willemen
Primary Contact  _

Johan M.J. Van den Bergh

Sarah M. Bonte

Sébastien Anguille

Carlo Heirman

Barbara M.H. Stein

Herman Goossens

Tessa Kerre

Kris Thielemans

Marc Peeters

Viggo F.I. Van Tendeloo

Evelien L.J. Smits

Zwi N. Berneman


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12170